A. O. Ozen Et Al. , "A phase 2/3 study evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE disease)," vol.228, pp.9, 0
Ozen, A. O. Et Al. A phase 2/3 study evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE disease). , 9.
Ozen, A. O., Chongsrisawat, V., Sefer, A., Kolukisa, B., Jalbert, J., Miller, J., ... Meagher, K. A phase 2/3 study evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE disease) . (pp.9).
Ozen, AHMET Et Al. "A phase 2/3 study evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE disease),"
Ozen, AHMET O. Et Al. "A phase 2/3 study evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE disease)." , pp.9
Ozen, A. O. Et Al. . "A phase 2/3 study evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE disease)." , p.9.
@conferencepaper{conferencepaper, author={AHMET OĞUZHAN ÖZEN Et Al. }, title={A phase 2/3 study evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE disease)}, congress name={}, city={}, country={}, year={0}, pages={9} }